508
Participants
Start Date
March 31, 2005
Primary Completion Date
April 30, 2008
Study Completion Date
December 31, 2009
infliximab infusion; AZA placebo caps
Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
infliximab (IFX) infusion; azathioprine (AZA) caps
AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
infliximab (IFX) placebo infusion; azathioprine (AZA) caps
AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
Birmingham
Phoenix
Orange
Roseville
San Diego
San Luis Obispo
Golden
Littleton
Hartford
Gainesville
Jacksonville
North Miami Beach
Winter Park
Austell
Decatur
Savannah
Peoria
Clive
Overland Park
Topeka
Baton Rouge
Metairie
Troy
Plymouth
Rochester
Ocean Springs
Tupelo
St Louis
Urbana
Lincoln
Egg Harbor
Great Neck
New Hyde Park
New York
Asheville
Charlotte
Raleigh
Wilmington
Bend
Portland
Hatfield
Lancaster
Philadelphia
Pittsburgh
Columbia
Austin
Houston
San Antonio
Bellevue
Spokane
Tacoma
Hall in Tirol
Vienna
Bonheiden
Brussels
Leuven
Liège
Roeselare
Montreal
Toronto
Québec
Aalborg
Aarhus C
Helsinge
Amiens
Bordeaux
Caen
Grenoble
Lille
Nancy
Paris
Toulouse
Berlin
Frankfurt am Main
Hamburg
Hanover
Herne
Kiel
Magdeburg
Mainz
Minden
München
Münster
Athens
Eksochi
Heraklion- Crete
Nicea
Haifa
Jerusalem
Kfar Saba
Petah Tikva
Tel Aviv
Dordrecht
Eindhoven
Rotterdam
Oslo
Amadora
Coimbra
Barcelona
Madrid
Santander
Santiago de Compostela
Seville
Valencia
Linköping
Lund
Stockhollm
Stockholm
Bristol
Cambridge
Leeds
Livingston
London
Newcastle upon Tyne
Stockport
Collaborators (1)
Schering-Plough
INDUSTRY
Centocor Ortho Biotech Services, L.L.C.
INDUSTRY